-
European Radiology: AI-assisted biparametric MRI prostate cancer surveillance
Time of Update: 2023-01-04
Recently, a study published in the journal European Radiology evaluated the feasibility of artificial intelligence-assisted biparametric MRI (bpMRI) in automatically detecting csPCa, providing technical support for faster and more accurate clinical diagnosis of PCa. This retrospective study included 1513 patients who underwent bpMRI (T2+DWI) between 2014 and 2020, of whom 73 received at least two consecutive bpMRI scans and repeat biopsies.
-
European Radiology: Application of T1 mapping and ADC histogram parameters in predicting meningioma's grade, subtype, and proliferative activity
Time of Update: 2023-01-04
The prospective study included 69 patients with meningioma, each of whom underwent preoperative MRI, including T1mapping and DWI sequences 。 Histogram metrics were extracted from the entire tumor and peritumor edema using FeAture Explorer, including mean, median, maximum, minimum, 10th percentile (C10), 90th percentile (C90), kurtosis, skewness, and variance, and apparent diffusion coefficient (ADC) values.
-
J Clin Oncol: Risk factors associated with adjuvant therapy for colon cancer oxaliplatin-induced peripheral neuropathy
Time of Update: 2023-01-04
The objective of the CALGB/SWOG 80702 study was to evaluate the association of length of treatment, celecoxib use, physical activity, body mass index (BMI), diabetes, and vitamin B6 with oxaliplatin-induced peripheral neuropathy (OPIN) in patients with stage III colon cancer.
-
Nature sub-journal: Sun Yat-sen University Song Erwei/Luo Manli discovered potential new mechanism of aromatase inhibitor resistance in breast cancer
Time of Update: 2023-01-04
On November 22, 2022, Sun Yat-sen University Song Erwei and Luo Manli jointly published a report on Nature Communications The study paper "Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer," which showed aromatase inhibitors (AI).
-
J Clin Oncol: CD19 and CD22 targeting chimeric antigen receptor T cells in combination therapy for childhood B-cell acute lymphoblastic leukemia
Time of Update: 2023-01-04
The study is a Phase II clinical trial to evaluate the safety and efficacy of CD19 and CD22 chimeric antigen receptor T cells in combination in patients with refractory disease or high-risk hematological disorders or extramedullary recurrence of B acute lymphoblastic leukemia.
-
European Radiology: Imaging screening value for bone metastases in prostate cancer
Time of Update: 2023-01-04
Current guidelines from the European Urological Association (EAU) recommend a bone scan (BS) in prostate cancer patients to detect bone metastases and abdominal cross-sectional imaging with lymph node staging to confirm the stage in patients at intermediate and high risk.
-
A summary of the series of studies of atezolizumab (T drug) in lung cancer
Time of Update: 2023-01-04
and atezolizumab + carboplatin + paclitaxel (ACP group) compared with bevacizumab + carboplatin + paclitaxel (BCP group) for first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) The final overall survival time (OS) results were performed with subgroup analysis of EGFR-sensitive mutations, liver metastases, and PD-L1 expression status.
-
European Radiology: Comparison of uptake of [68Ga]Ga-FAPI and [18F]FDG in patients with gastric ring-ring cell carcinoma
Time of Update: 2023-01-04
Recently, a study published in the journal European Radiology explored the tumor detection and accuracy of [68Ga]Ga-FAPI PET imaging in primary and metastatic GSRCC and compared the results with [18F]FDG PET.
-
European Radiology: How to shorten whole-body MRI imaging to detect bone metastases and myeloma?
Time of Update: 2023-01-04
F Gallium-68 PET/CT fusion images showing the same two lesions showing tracer uptakeThis study in patients with bone metastases or MM showed that shorter WB-MRI protocols relying on a single T2 Dixon sequence with fat and water reconstruction can replace the reference T1+STIR sequence for bone screening, resulting in shorter examination times without loss of diagnostic accuracy.
-
Stop taking vitamin tablets! The latest study: may lead to a 27% increase in the incidence of cancer and more than 2 times the risk of brain metastases
Time of Update: 2023-01-04
Is it necessary to eat some vitamin C lozenges or use a multivitamin directly?In fact, in June this year, JAMA published such a blockbuster review Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer, which is part of the US Preventive Services Task Force (USPSTF).
-
Lancet Oncol: 5-year prognosis for stereotactic ablative radiotherapy for primary renal cell carcinoma
Time of Update: 2023-01-04
The primary objective of the study was to report on the long-term efficacy and safety of SABR in the treatment of localized renal cell carcinoma.
The primary objective of the study was to report on the long-term efficacy and safety of SABR in the treatment of localized renal cell carcinoma.
-
European Radiology: Anterior chamber fortification predicts optic nerve invasion in retinoblastoma!
Time of Update: 2023-01-04
This study reveals a correlation between anterior chamber GBCA enhancement and optic nerve invasion in retinoblastoma, which may be due to intraorbital lymphatic dysfunction, and may serve as an important indication of increased brain GBCA excretion in the diagnosis of neurological pathology.
-
European Radiology: How to distinguish peritumoral abnormalities in enhanced CT after implantation of liver malignant particles?
Time of Update: 2023-01-04
b A 78-year-old woman with rectal cancer appears at 5 months with a new oval-shaped protrusion (orange arrow) next to the particle, appearing as a high-density ring that surrounds a low-density This study found that the characteristics of the described radioactive particle-induced peritumor response were associated with higher doses and lower rates of local progression.
-
NAR: Dongyu Zhao et al. of Peking University reveal the underlying mechanism of CHD6 transcriptional activation of carcinogenic pathways
Time of Update: 2023-01-04
1093/nar/gkac1090 Although CHD6 is a member of the chromatin domain helicase DNA-binding protein family, little is known about its exact role in chromatin remodeling or cancer disease.
-
EMBO J: Li Binghui's team at Capital Medical University found that stearate-derived ultra-long-chain fatty acids affect tumor growth
Time of Update: 2023-01-04
Seven malonyl-CoA molecules act as extension units, together with acetyl-CoA as a starter, catalyzed by fatty acid synthase (FASN) to form a 16-carbon saturated fatty acid palmitate 。 In contrast, malonyl-CoA synthesized by ACC2 is located near the surface of mitochondria and is thought to be an inhibitor of carnitine palmitoyl transferase 1 (CPT1), thereby regulating the transport of long-chain fatty acids to mitochondria for subsequent use β - oxidation.
-
Advanced Functional Materials: New applications of iron death: Chinese scholars develop cancer diagnosis and collaborative therapy based on iron death
Time of Update: 2023-01-04
Recently, the Qin Yan research group of the Institute of Biophysics of the Chinese Academy of Sciences cooperated with Professor Jianzhuang Jianzhuang and Professor Wang Tianyu of the University of Science and Technology Beijing to publish a title in the journal Advanced Functional Materials Research paper on Modulated ultrasmall γ-Fe2O3 nanocrystal assembles for switchable magnetic resonance imaging and photothermal-ferroptotic-chemical synergistic cancer therapy.
-
Astellas' first Claudin18.2 antibody Zolbetuximab was successfully clinically successful in the treatment of Cldn18.2-positive gastric adenocarcinoma or gastroesophageal junction adenocarcinoma stage III
Time of Update: 2023-01-04
On November 16, 2022, Astellas announced positive top-line results from a Phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of Claudin18.
2 antibody zolbetuximab in combination with mFOLFOX6, a drug combination regimen including oxaliplatin, calcium folinate, and fluorouracil 。 The SPOTLIGHT trial enrolled 566 patients with cldn 18.
-
Int J Urol: Active surveillance questionnaire for patients with low- and intermediate-risk prostate cancer
Time of Update: 2023-01-04
Recently, researchers from Japan published an article in Int J Urol, where they conducted a nationwide questionnaire survey to understand active surveillance (AS) for low- and intermediate-risk prostate cancer (PCa).
-
Cell: Nobel laureate's latest Cell paper: A large number of viruses exist in the CRISPR system, from which smaller and more efficient Cas enzymes are mined
Time of Update: 2023-01-04
On November 23, 2022, Jennifer Doudna, Nobel Prize winner and CRISPR gene editing pioneer, and others published a research paper in the journal Cell entitled: Diverse virus-encoded CRISPR-Cas systems include streamlined genome editors [3].
-
Advanced Materials: Wang Hai's team from the National Nano Center has made a new breakthrough in tumor nanovaccines
Time of Update: 2023-01-04
On November 11, 2022, Hai Wang's research team published a research paper entitled: Stabilizing RNA Nanovaccines with Transformable Hyaluronan Dynamic Hydrogel for Durable Cancer Immunotherapy in the journal Advanced Functional Materials。In this study, a hydrogel-LNPs system (HA-mRLNPs) was developed that can efficiently deliver mRNA encoding tumor antigens to dendritic cells for antigen presentation, inducing antigen-specific CD8+ T cells to kill tumor cells.
